Equities Analysts Set Expectations for Zoetis Q4 Earnings

Zoetis Inc. (NYSE:ZTS) – Investment analysts at Zacks Research dropped their Q4 2025 earnings estimates for shares of Zoetis in a report released on Monday, November 24th. Zacks Research analyst Team now anticipates that the company will earn $1.39 per share for the quarter, down from their prior forecast of $1.50. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.77 EPS, Q4 2026 earnings at $1.66 EPS and Q2 2027 earnings at $1.91 EPS.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.

Several other equities research analysts have also recently weighed in on ZTS. BTIG Research dropped their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. UBS Group decreased their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Finally, Morgan Stanley dropped their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, November 10th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Stock Down 0.1%

NYSE ZTS opened at $127.78 on Wednesday. Zoetis has a 1 year low of $115.25 and a 1 year high of $181.85. The stock has a market capitalization of $56.31 billion, a PE ratio of 21.99, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business’s 50-day moving average is $136.51 and its 200 day moving average is $149.48.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is 33.67%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ZTS. Norges Bank bought a new position in shares of Zoetis during the second quarter valued at approximately $809,491,000. Nuveen LLC bought a new stake in shares of Zoetis in the 1st quarter worth approximately $616,375,000. Diamond Hill Capital Management Inc. purchased a new stake in shares of Zoetis in the 3rd quarter worth approximately $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares in the last quarter. Finally, Polen Capital Management LLC increased its position in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.